Stockreport

Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermato...

SIENNA BIOPHARMACEUTICALS  (SNNA) 
Last sienna biopharmaceuticals earnings: 8/8 04:18 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.siennabio.com/node/5806
PDF -- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- [Read more]